Impact of low-intensity electric field therapy on malignant pleural mesothelioma cell proliferation

Trabectedin is a drug that binds to the minor groove of DNA, alkylating guanine at the N2 position and with an original mechanism of action involving the nucleotide excision repair machinery.

The clinical study investigating the anti-CTLA-4 human monoclonal antibody (mAb) tremelimumab in the immunotherapy of malignant mesothelioma was initiated in 2009.

Many malignant pleural mesothelioma (MPM) patients are candidates for chemotherapy with a single agent or in combination with other treatments.